CU20120153A7 - Antígenos vacunales quiméricos contra el virus de la hepatitis c - Google Patents
Antígenos vacunales quiméricos contra el virus de la hepatitis cInfo
- Publication number
- CU20120153A7 CU20120153A7 CUP2012000153A CU20120153A CU20120153A7 CU 20120153 A7 CU20120153 A7 CU 20120153A7 CU P2012000153 A CUP2012000153 A CU P2012000153A CU 20120153 A CU20120153 A CU 20120153A CU 20120153 A7 CU20120153 A7 CU 20120153A7
- Authority
- CU
- Cuba
- Prior art keywords
- virus
- antigens
- chimeric
- chemical
- against hepatitis
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 6
- 102000036639 antigens Human genes 0.000 title abstract 6
- 108091007433 antigens Proteins 0.000 title abstract 6
- 241000711549 Hepacivirus C Species 0.000 title abstract 4
- 239000000126 substance Substances 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24271—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención describe antígenos vacunales quiméricos contra el virus de la hepatitis C (VHC) que comprenden regiones seleccionadas de diferentes antígenos de dicho virus, las que se ubican en un orden determinado dentro del polipéptido. Dichos antígenos quiméricos, además, pueden incluir epitopos específicos para linfocitos T auxiliadores, diseñados de forma artificial. Los antígenos quiméricos, así como las composiciones vacunales resultantes, son aplicables a la esfera de la medicina y la industria farmacéutica, y tienen un uso profiláctico y/o terapéutico contra el VHC. Las composiciones vacunales de la invención generan una respuesta inmune potente y de amplio espectro contra diferentes antígenos de dicho virus, con un mínimo de componentes.
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20120153A CU24112B1 (es) | 2012-11-05 | 2012-11-05 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
| ES13801461.8T ES2644801T3 (es) | 2012-11-05 | 2013-10-28 | Antígenos de vacuna quimérica contra el virus de la hepatitis c |
| MX2015005651A MX358507B (es) | 2012-11-05 | 2013-10-28 | Antigenos vacunales quimericos contra el virus de la hepatitis c. |
| IN3925DEN2015 IN2015DN03925A (es) | 2012-11-05 | 2013-10-28 | |
| PCT/CU2013/000006 WO2014067498A1 (es) | 2012-11-05 | 2013-10-28 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
| AU2013339846A AU2013339846B2 (en) | 2012-11-05 | 2013-10-28 | Chimeric vaccine antigens against hepatitis C virus |
| US14/440,443 US9676825B2 (en) | 2012-11-05 | 2013-10-28 | Chimeric vaccine antigens against hepatitis C virus |
| CA2901346A CA2901346C (en) | 2012-11-05 | 2013-10-28 | Chimeric vaccine antigens against hepatitis c virus |
| CN201380064380.9A CN104837498B (zh) | 2012-11-05 | 2013-10-28 | 针对丙型肝炎病毒的嵌合疫苗抗原 |
| EP13801461.8A EP2915544B1 (en) | 2012-11-05 | 2013-10-28 | Chimeric vaccine antigens against hepatitis c virus |
| RU2015121429A RU2639504C2 (ru) | 2012-11-05 | 2013-10-28 | Химерные антигены для вакцины против вируса гепатита с |
| JP2015540044A JP6259831B2 (ja) | 2012-11-05 | 2013-10-28 | C型肝炎ウイルスに対するキメラワクチン抗原 |
| KR1020157012656A KR102093495B1 (ko) | 2012-11-05 | 2013-10-28 | C형 간염 바이러스에 대한 키메라 백신 항원 |
| ARP130104019A AR093341A1 (es) | 2012-11-05 | 2013-11-04 | Antigenos vacunales quimericos contra el virus de la hepatitis c |
| ZA2015/03036A ZA201503036B (en) | 2012-11-05 | 2015-05-04 | Chimeric vaccine antigens against hepatitis c virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20120153A CU24112B1 (es) | 2012-11-05 | 2012-11-05 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20120153A7 true CU20120153A7 (es) | 2014-06-27 |
| CU24112B1 CU24112B1 (es) | 2015-08-27 |
Family
ID=49724426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20120153A CU24112B1 (es) | 2012-11-05 | 2012-11-05 | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9676825B2 (es) |
| EP (1) | EP2915544B1 (es) |
| JP (1) | JP6259831B2 (es) |
| KR (1) | KR102093495B1 (es) |
| CN (1) | CN104837498B (es) |
| AR (1) | AR093341A1 (es) |
| AU (1) | AU2013339846B2 (es) |
| CA (1) | CA2901346C (es) |
| CU (1) | CU24112B1 (es) |
| ES (1) | ES2644801T3 (es) |
| IN (1) | IN2015DN03925A (es) |
| MX (1) | MX358507B (es) |
| RU (1) | RU2639504C2 (es) |
| WO (1) | WO2014067498A1 (es) |
| ZA (1) | ZA201503036B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2986342C (en) | 2015-07-07 | 2024-04-02 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
| AU2017332854B2 (en) | 2016-09-21 | 2024-11-14 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
| US11596679B2 (en) * | 2017-04-27 | 2023-03-07 | Vanderbilt University | Hepatitis C virus gene sequences and methods of use therefor |
| CN112601548A (zh) * | 2018-03-16 | 2021-04-02 | 艾伯塔大学理事会 | 丙型肝炎病毒肽组合物及其使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60039715D1 (de) | 1999-11-19 | 2008-09-11 | Csl Ltd | Hcv-impfstoff zusammensetzungen |
| US6544780B1 (en) * | 2000-06-02 | 2003-04-08 | Genphar, Inc. | Adenovirus vector with multiple expression cassettes |
| CU23496A1 (es) | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| JP5405832B2 (ja) * | 2006-01-04 | 2014-02-05 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | Hcv特異的なt細胞の活性化 |
| US7256008B2 (en) | 2006-01-06 | 2007-08-14 | Abbott Laboratories | Determination of concentration of FK778 by competitive immunoassay |
| US20110110974A1 (en) | 2007-10-29 | 2011-05-12 | Erik Depla | Methods and kits for inducing a ctl response using a prime boost regimen |
| JP5593220B2 (ja) * | 2008-04-25 | 2014-09-17 | 東レ株式会社 | C型肝炎ウイルス由来のキメラ遺伝子を含む核酸 |
| EP2331125A4 (en) * | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| US20110311550A1 (en) * | 2008-10-24 | 2011-12-22 | The Scripps Research Institute | Agents for hcv treatment |
-
2012
- 2012-11-05 CU CU20120153A patent/CU24112B1/es active IP Right Grant
-
2013
- 2013-10-28 KR KR1020157012656A patent/KR102093495B1/ko not_active Expired - Fee Related
- 2013-10-28 ES ES13801461.8T patent/ES2644801T3/es active Active
- 2013-10-28 RU RU2015121429A patent/RU2639504C2/ru not_active IP Right Cessation
- 2013-10-28 JP JP2015540044A patent/JP6259831B2/ja not_active Expired - Fee Related
- 2013-10-28 MX MX2015005651A patent/MX358507B/es active IP Right Grant
- 2013-10-28 CN CN201380064380.9A patent/CN104837498B/zh not_active Expired - Fee Related
- 2013-10-28 CA CA2901346A patent/CA2901346C/en not_active Expired - Fee Related
- 2013-10-28 US US14/440,443 patent/US9676825B2/en not_active Expired - Fee Related
- 2013-10-28 AU AU2013339846A patent/AU2013339846B2/en not_active Ceased
- 2013-10-28 IN IN3925DEN2015 patent/IN2015DN03925A/en unknown
- 2013-10-28 WO PCT/CU2013/000006 patent/WO2014067498A1/es not_active Ceased
- 2013-10-28 EP EP13801461.8A patent/EP2915544B1/en active Active
- 2013-11-04 AR ARP130104019A patent/AR093341A1/es unknown
-
2015
- 2015-05-04 ZA ZA2015/03036A patent/ZA201503036B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2015DN03925A (es) | 2015-10-02 |
| KR102093495B1 (ko) | 2020-03-26 |
| JP6259831B2 (ja) | 2018-01-10 |
| US20150307558A1 (en) | 2015-10-29 |
| CU24112B1 (es) | 2015-08-27 |
| KR20150079694A (ko) | 2015-07-08 |
| EP2915544B1 (en) | 2017-08-09 |
| JP2015536936A (ja) | 2015-12-24 |
| AU2013339846B2 (en) | 2017-08-17 |
| MX358507B (es) | 2018-08-22 |
| US9676825B2 (en) | 2017-06-13 |
| MX2015005651A (es) | 2015-08-20 |
| CN104837498B (zh) | 2018-05-18 |
| CN104837498A (zh) | 2015-08-12 |
| ES2644801T3 (es) | 2017-11-30 |
| CA2901346A1 (en) | 2014-05-08 |
| ZA201503036B (en) | 2016-01-27 |
| WO2014067498A1 (es) | 2014-05-08 |
| RU2639504C2 (ru) | 2017-12-21 |
| AR093341A1 (es) | 2015-06-03 |
| RU2015121429A (ru) | 2016-12-27 |
| AU2013339846A1 (en) | 2015-05-14 |
| EP2915544A1 (en) | 2015-09-09 |
| CA2901346C (en) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001610A1 (es) | Anticuerpos humanos para hemagglutinina de influenza | |
| NI201800052A (es) | Anticuerpos que neutraliza el virus respiratorio sincitial humano | |
| CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
| JOP20190097A1 (ar) | الجلوبولينات المناعية واستخداماتها | |
| ZA201803978B (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| MX2018007288A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| EA201591164A1 (ru) | Вакцины против вируса гриппа и их применение | |
| MX391015B (es) | Composiciones de nanoparticulas y usos de las mismas | |
| MX370191B (es) | Composiciones y su uso en el tratamiento de la inmunodeficiencia. | |
| MX2015016627A (es) | Vacuna para la malaria. | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| EP3491026A4 (en) | HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES | |
| MX342716B (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| MX2016016533A (es) | Combinaciones inmunogenas. | |
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| MX364689B (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| MX391149B (es) | Vacunas contra el virus de inmunodeficiencia humana (vih) que comprenden uno o mas antigenos episensus de poblacion. | |
| IL262514A (en) | Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| MX2017015462A (es) | Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas. | |
| AR093341A1 (es) | Antigenos vacunales quimericos contra el virus de la hepatitis c | |
| EP3615054A4 (en) | NUCLEOSIDE-MODIFIED MRNA LIPID NANOPARTICLE VACCINE FOR HEPATITIS C VIRUS | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| IN2014DN09445A (es) | ||
| MX2016004754A (es) | Nuevo peptido que tiene cuatro epitopos de linfocitos t citotoxicos (ctl) enlazados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |